|Study Title:||Canadian MS Pregnancy Prospective Cohort Study (CANPREG-MS)|
|Study Description:||MS is the most commonly acquired neurological disorder affecting adults of reproductive age. This 5-year study emerged in response to an increasing need by women with MS for evidence-based, up-to-date, and personalized information surrounding reproductive issues and childbearing. We will establish a prospective CANPREG-MS study that will identify pregnancies in women with MS, obtain information on the disease and the medications used for MS treatment at conception, during gestation (pregnancy) and while breast-feeding if appropriate. We will follow mothers and their infants from conception to one year postpartum (i.e. after delivery) to determine the health status of mothers and their babies. We will also include women with MS who are planning a pregnancy.
If you agree to be in this study, we would call you to complete study questionnaires.
1. Initial interview (for all participants) – we will ask about you (e.g. month/year of birth, ethnicity, education), your family history, general health conditions and MS during this 45 minutes interview.
2. Follow-up interview
a. For participants who are planning to become pregnant, you will be followed every 6-months (unless we are being informed about a pregnancy in the interim) with a 20-minute interview.
b. For participants who are pregnant, you will be contacted at the 6-months gestation. Then, you will be interviewed at 1, 2, 4, 6, 9, 12-months post-partum (after delivery). Each interview will be about 45 minutes long.
We will use the findings of this study to develop an educational resource that is responsive to concerns of women with MS to help in making the personal decision about pregnancy.
|Recruitment Dates:||2017-11-01 to 2022-04-03|
|Who can participate:||All women with a confirmed diagnosis of MS aged 18 or older who are pregnant or planning a pregnancy|
|Location of Trial:||British Columbia|
|Contact Information:||Dr. Dessa Sadovnick
MS research dedicated phone number (no charge to you) at 1-800-668-2291 or email us at